Intestifalk (Budesonide)

Budesonide binds to glucocorticoid receptors inside cells, modulating gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces leukocyte infiltration and stabilises cell membranes, providing a strong local anti‑inflammatory and immunosuppressive effect within the rectal and colonic tissues.

The specific dose and duration of Intestifalk are determined by the prescribing clinician based on disease severity, patient response, and treatment guidelines. Healthcare professionals tailor the regimen to each individual, and patients should follow the prescriber’s instructions without alteration.

Safety data for budesonide rectal use in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against any possible risks to the fetus or infant. If treatment is necessary, it should be administered under close medical supervision.

To request Intestifalk, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Intestifalk delivers budesonide locally, offering high anti‑inflammatory potency with minimal systemic absorption compared with oral corticosteroids. This can reduce the risk of systemic side effects while effectively treating distal disease. It is often preferred when topical therapy is appropriate, whereas systemic agents are reserved for more extensive disease.

Intestifalk should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of direct sunlight and away from sources of humidity to maintain its stability and efficacy.

Intestifalk is administered rectally, typically as a suppository or enema, according to the prescriber’s instructions. The patient inserts the dose into the rectum, allowing the medication to dissolve and act directly on the inflamed mucosa.

Serious risks include severe allergic reactions (anaphylaxis), systemic corticosteroid effects such as adrenal suppression, and rare complications like perforated colon or significant intra‑ocular pressure elevation. Patients should seek immediate medical attention if they experience symptoms such as intense abdominal pain, vision changes, or signs of an allergic reaction.

Intestifalk is contraindicated in patients with known hypersensitivity to budesonide or any formulation components, active systemic infections, or those who have experienced severe adverse reactions to corticosteroids. It should also be used with caution in individuals with uncontrolled diabetes, hypertension, or glaucoma, and only under medical supervision.